Supplement Scholar
Bioregulator

Cortagen

Research compound. This is not a dietary supplement. Unless it is identified as an approved prescription drug, it is not approved by the FDA for human use. This page summarizes published research for education only; we do not sell it or link to sellers.

Cortagen. Four-amino-acid Khavinson bioregulator proposed to support brain tissue; evidence is mostly Russian animal research.

How it works. Proposed to regulate gene expression in brain cells. The mechanism is not established.

What the research supports. 1 graded claims. Strongest: Peripheral nerve regeneration in animals (preclinical).

Side effects and interactions. 0 medication interactions listed. Serious: Unknown long-term safety.

Common forms. Available as Injection or oral (research).

Community. Experiences from people who have tried Cortagen. Anecdotes are not medical advice.

Cortagen. Four-amino-acid Khavinson bioregulator proposed to support brain tissue; evidence is mostly Russian animal research.

4-residue chainC17H26N4O9 · 430.4 g/mol

What it is

A synthetic Ala-Glu-Asp-Pro tetrapeptide. Studies report effects on nerve regeneration and brain gene expression in animals, largely from one research school.

Also called

Ala-Glu-Asp-ProAEDP

How it works

Proposed to regulate gene expression in brain cells. The mechanism is not established.

Pathways

  • Neural gene expression (proposed)

Effects

  • +Nerve regeneration (animal studies) supports

What the research supports

Peripheral nerve regeneration in animalspreclinical

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Side effects & interactions

Common side effects

  • Few side effects reported; data limited

Serious

  • Unknown long-term safety

No notable medication interactions listed.

Check any supplement–medication combination with your pharmacist before starting.

Common forms

  • Injection or oral (research)

Discussion

Loading discussion…